ADC Therapeutics SA
ADCT4.460USD
-0.175-3.78%
收盤 10/31, 16:00（美東）報價延遲15分鐘
501.75M總市值
虧損本益比TTM
關於 ADC Therapeutics SA 公司
ADC Therapeutics SA 是一家總部位於瑞士的臨牀階段腫瘤藥物發現和開發公司。該公司開發抗體藥物偶聯物 (ADC)，用於治療實體癌和血液癌。該公司採用針對特定腫瘤抗原的單克隆抗體與一類基於吡咯並苯二氮卓 (PBD) 的彈頭結合，以選擇性地靶向和殺死癌細胞。該公司有多個基於 PBD 的 ADC 正在進行臨牀試驗，從首次人體試驗到關鍵的 II 期臨牀試驗，以及許多正在開發的臨牀前 ADC。其主要候選藥物是用於治療淋巴瘤和白血病的 ADCT-301 和用於治療非霍奇金淋巴瘤和 B 細胞白血病的 ADCT-402。該公司爲美國、瑞士和英國的客戶提供服務。
ADC Therapeutics SA簡介
公司代碼ADCT
公司名稱ADC Therapeutics SA
上市日期May 15, 2020
CEOMr. Ameet Mallik
員工數量263
證券類型Ordinary Share
年結日May 15
公司地址Biopole
城市EPALINGES
上市交易所NYSE Consolidated
國家Switzerland
郵編1066
電話41216530200
網址https://adctherapeutics.com/
公司代碼ADCT
上市日期May 15, 2020
CEOMr. Ameet Mallik
ADC Therapeutics SA公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
+1.60%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
1.55M
-1.70%
Mr. Mohamed Zaki, M.D., Ph.D.
Mr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
642.33K
+50.70%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
404.81K
+0.52%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
361.04K
-11.63%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Vice Chairman of the Board, Lead Independent Director
Non-Executive Vice Chairman of the Board, Lead Independent Director
180.50K
+26.54%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Independent Director
Non-Executive Independent Director
134.98K
+38.35%
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
99.40K
+38.06%
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Non-Executive Independent Director
Non-Executive Independent Director
55.26K
+98.35%
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Director
Director
40.00K
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
+1.60%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
1.55M
-1.70%
Mr. Mohamed Zaki, M.D., Ph.D.
Mr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
642.33K
+50.70%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
404.81K
+0.52%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
361.04K
-11.63%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Vice Chairman of the Board, Lead Independent Director
Non-Executive Vice Chairman of the Board, Lead Independent Director
180.50K
+26.54%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 10月2日 週四
更新時間: 10月2日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Redmile Group, LLC
13.93%
Prosight Capital
9.30%
HPWH TH AG
7.71%
Point72 Asset Management, L.P.
6.90%
OrbiMed Advisors, LLC
5.25%
其他
56.91%
持股股東
持股股東
佔比
Redmile Group, LLC
13.93%
Prosight Capital
9.30%
HPWH TH AG
7.71%
Point72 Asset Management, L.P.
6.90%
OrbiMed Advisors, LLC
5.25%
其他
56.91%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
22.78%
Hedge Fund
19.46%
Corporation
9.69%
Investment Advisor
9.20%
Research Firm
6.61%
Individual Investor
5.81%
Private Equity
5.25%
Bank and Trust
0.86%
Insurance Company
0.02%
其他
20.31%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
184
72.23M
64.20%
+2.08M
2025Q2
209
87.64M
88.37%
-14.63M
2025Q1
217
80.51M
81.56%
-23.93M
2024Q4
219
81.03M
83.80%
-19.29M
2024Q3
223
79.78M
82.57%
-21.86M
2024Q2
215
76.61M
81.35%
-7.96M
2024Q1
177
59.13M
71.30%
-27.56M
2023Q4
169
58.32M
71.49%
-25.86M
2023Q3
180
68.48M
85.02%
-18.63M
2023Q2
182
74.11M
92.00%
-12.88M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Redmile Group, LLC
15.67M
13.93%
--
--
Jun 30, 2025
Prosight Capital
10.47M
9.3%
+924.77K
+9.69%
Jun 30, 2025
HPWH TH AG
8.67M
7.71%
-1.12M
-11.42%
May 15, 2025
Point72 Asset Management, L.P.
7.76M
6.9%
+7.76M
--
Jun 30, 2025
OrbiMed Advisors, LLC
5.91M
5.25%
-61.10K
-1.02%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.06M
3.6%
-442.92K
-9.85%
Jun 30, 2025
Oaktree Capital Management, L.P.
4.02M
3.57%
+4.02M
--
Apr 25, 2024
Morgan Stanley & Co. LLC
2.99M
2.66%
+33.76K
+1.14%
Jun 30, 2025
Heights Capital Management, Inc.
2.83M
2.52%
+2.83M
--
Jun 30, 2025
Nantahala Capital Management, LLC
2.27M
2.01%
+2.27M
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 10月6日 週一
更新時間: 10月6日 週一
機構名稱
佔比
iShares Micro-Cap ETF
0.05%
iShares Biotechnology ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.05%
iShares Biotechnology ETF
佔比0.02%
ProShares UltraPro Russell2000
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
iShares Russell 2000 Growth ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
Fidelity Enhanced Small Cap ETF
佔比0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
